structural heart disease

1 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Anteris Technologies Global Corp.

Anteris Secures $320M Funding as DurAVR Heart Valve Advances to Global Trials

Anteris secures $320M funding to advance DurAVR heart valve through global trials, with FDA approval and increased clinical development spending.
MDTAVRFDA approvalclinical trial